These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26064876)

  • 41. The AChE membrane-binding tail PRiMA is down-regulated in muscle and nerve of mice with muscular dystrophy by merosin deficiency.
    Vidal CJ; Montenegro MF; Muñoz-Delgado E; Campoy FJ; Cabezas-Herrera J; Moral-Naranjo MT
    Chem Biol Interact; 2013 Mar; 203(1):330-4. PubMed ID: 22906800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. γ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort.
    Dalichaouche I; Sifi Y; Roudaut C; Sifi K; Hamri A; Rouabah L; Abadi N; Richard I
    Muscle Nerve; 2017 Jul; 56(1):129-135. PubMed ID: 27759885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.
    Minetti GC; Colussi C; Adami R; Serra C; Mozzetta C; Parente V; Fortuni S; Straino S; Sampaolesi M; Di Padova M; Illi B; Gallinari P; Steinkühler C; Capogrossi MC; Sartorelli V; Bottinelli R; Gaetano C; Puri PL
    Nat Med; 2006 Oct; 12(10):1147-50. PubMed ID: 16980968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Removing the immune response from muscular dystrophy research.
    Chamberlain JS
    Mol Ther; 2013 Oct; 21(10):1821-2. PubMed ID: 24081124
    [No Abstract]   [Full Text] [Related]  

  • 45. The Rag2⁻Il2rb⁻Dmd⁻ mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies.
    Vallese D; Negroni E; Duguez S; Ferry A; Trollet C; Aamiri A; Vosshenrich CA; Füchtbauer EM; Di Santo JP; Vitiello L; Butler-Browne G; Mouly V
    Mol Ther; 2013 Oct; 21(10):1950-7. PubMed ID: 23975040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantification of the mechanical behavior of carotid arteries from wild-type, dystrophin-deficient, and sarcoglycan-delta knockout mice.
    Gleason RL; Dye WW; Wilson E; Humphrey JD
    J Biomech; 2008 Nov; 41(15):3213-8. PubMed ID: 18842267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Halofuginone and muscular dystrophy.
    Pines M; Halevy O
    Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy.
    Millay DP; Sargent MA; Osinska H; Baines CP; Barton ER; Vuagniaux G; Sweeney HL; Robbins J; Molkentin JD
    Nat Med; 2008 Apr; 14(4):442-7. PubMed ID: 18345011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular and genetic mapping of the mouse mdx locus.
    Cavanna JS; Coulton G; Morgan JE; Brockdorff N; Forrest SM; Davies KE; Brown SD
    Genomics; 1988 Nov; 3(4):337-41. PubMed ID: 3243547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sensorineural hearing loss in the mdx mouse: a model of Duchenne muscular dystrophy.
    Raynor EM; Mulroy MJ
    Laryngoscope; 1997 Aug; 107(8):1053-6. PubMed ID: 9261007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new genetic variant of mdx mice: study of the phenotype.
    Krivov LI; Stenina MA; Yarygin VN; Polyakov AV; Savchuk VI; Obrubov SA; Komarova NV
    Bull Exp Biol Med; 2009 May; 147(5):625-9. PubMed ID: 19907755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac function in muscular dystrophy associates with abdominal muscle pathology.
    Gardner BB; Swaggart KA; Kim G; Watson S; McNally EM
    J Neuromuscul Dis; 2015; 2(1):39-49. PubMed ID: 26029630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel γ-sarcoglycan interactors in murine muscle membranes.
    Smith TC; Vasilakos G; Shaffer SA; Puglise JM; Chou CH; Barton ER; Luna EJ
    Skelet Muscle; 2022 Jan; 12(1):2. PubMed ID: 35065666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice.
    Banks GB; Combs AC; Chamberlain JS
    Muscle Nerve; 2010 Aug; 42(2):268-70. PubMed ID: 20544945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe murine limb-girdle muscular dystrophy type 2C pathology is diminished by FTY720 treatment.
    Heydemann A
    Muscle Nerve; 2017 Sep; 56(3):486-494. PubMed ID: 27935071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The change in dystrophin phenotype in heterozygous mdx mice.
    Pagel C; Watt D; Naudeer S; Partridge T; Morgan J
    J Neuropathol Exp Neurol; 1991 May; 50(3):278-80. PubMed ID: 2022969
    [No Abstract]   [Full Text] [Related]  

  • 57. Pattern of X-chromosome inactivation as a key determinant of the clinicopathologic phenotype of Duchenne muscular dystrophy carriers.
    Matthews PM; Karpati G
    Neurology; 1996 Apr; 46(4):1189-91. PubMed ID: 8780133
    [No Abstract]   [Full Text] [Related]  

  • 58. Distinct genetic regions modify specific muscle groups in muscular dystrophy.
    Swaggart KA; Heydemann A; Palmer AA; McNally EM
    Physiol Genomics; 2011 Jan; 43(1):24-31. PubMed ID: 20959497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice.
    Heydemann A; Ceco E; Lim JE; Hadhazy M; Ryder P; Moran JL; Beier DR; Palmer AA; McNally EM
    J Clin Invest; 2009 Dec; 119(12):3703-12. PubMed ID: 19884661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The superhealing MRL background improves muscular dystrophy.
    Heydemann A; Swaggart KA; Kim GH; Holley-Cuthrell J; Hadhazy M; McNally EM
    Skelet Muscle; 2012 Dec; 2(1):26. PubMed ID: 23216833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.